Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) EBT Margin (2016 - 2025)

Dexcom (DXCM) has disclosed EBT Margin for 16 consecutive years, with 27.05% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 807.0% to 27.05% in Q4 2025 year-over-year; TTM through Dec 2025 was 23.35%, a 577.0% increase, with the full-year FY2025 number at 23.35%, up 577.0% from a year prior.
  • EBT Margin was 27.05% for Q4 2025 at Dexcom, down from 29.13% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 29.13% in Q3 2025 to a low of 5.74% in Q1 2022.
  • A 5-year average of 17.03% and a median of 17.53% in 2021 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: tumbled -1734bps in 2021, then skyrocketed 1129bps in 2025.
  • Dexcom's EBT Margin stood at 9.77% in 2021, then skyrocketed by 67bps to 16.34% in 2022, then skyrocketed by 46bps to 23.8% in 2023, then fell by -20bps to 18.98% in 2024, then soared by 43bps to 27.05% in 2025.
  • Per Business Quant, the three most recent readings for DXCM's EBT Margin are 27.05% (Q4 2025), 29.13% (Q3 2025), and 20.84% (Q2 2025).